These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30315835)

  • 1. OnabotulinumtoxinA for adductor spasmodic dysphonia (ADSD): Functional results and the role of dosage.
    Marchese MR; D'Alatri L; Bentivoglio AR; Paludetti G
    Toxicon; 2018 Dec; 155():38-42. PubMed ID: 30315835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective review of dosing trends in botulinum toxin injections for the treatment of adductor spasmodic dysphonia in a long-term cohort.
    French G; Bosch JD; Randall DR
    J Otolaryngol Head Neck Surg; 2020 Jan; 49(1):4. PubMed ID: 31937363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.
    Morzaria S; Damrose EJ
    J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of laryngeal botulinum toxin dosage to patient age, vitality, and socioeconomic issues.
    Young DL; Halstead LA
    J Voice; 2014 Sep; 28(5):614-7. PubMed ID: 24954039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of Onabotulinum Toxin A Treatment for Adductor Spasmodic Dysphonia and Laryngeal Tremor.
    Patel PN; Kabagambe EK; Starkweather JC; Keller M; Gamsarian V; Lee J; Kulkarni V; Garrett CG; Francis DO
    JAMA Otolaryngol Head Neck Surg; 2018 Apr; 144(4):293-299. PubMed ID: 29423509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adductor spasmodic dysphonia: Botulinum toxin a injections or laser thyroarytenoid myoneurectomy? A comparison from the patient perspective.
    Schuering JHC; Heijnen BJ; Sjögren EV; Langeveld APM
    Laryngoscope; 2020 Mar; 130(3):741-746. PubMed ID: 31169922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin treatment of false vocal folds in adductor spasmodic dysphonia: Functional outcomes.
    Simpson CB; Lee CT; Hatcher JL; Michalek J
    Laryngoscope; 2016 Jan; 126(1):118-21. PubMed ID: 26467807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment efficacy of electromyography versus fiberscopy-guided botulinum toxin injection in adductor spasmodic dysphonia patients: a prospective comparative study.
    Kim JW; Park JH; Park KN; Lee SW
    ScientificWorldJournal; 2014; 2014():327928. PubMed ID: 25383369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid-type Botulinum Toxin Type A in Adductor Spasmodic Dysphonia: A Prospective Pilot Study.
    Cha W; Jang JY; Wang SG; Kang JH; Jo MG
    J Voice; 2017 May; 31(3):378.e19-378.e24. PubMed ID: 27520509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Botulinum Toxin and Surgery among Spasmodic Dysphonia Patients.
    van Esch BF; Wegner I; Stegeman I; Grolman W
    Otolaryngol Head Neck Surg; 2017 Feb; 156(2):238-254. PubMed ID: 27803079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term botulinum toxin dose consistency for treatment of adductor spasmodic dysphonia.
    Holden PK; Vokes DE; Taylor MB; Till JA; Crumley RL
    Ann Otol Rhinol Laryngol; 2007 Dec; 116(12):891-6. PubMed ID: 18217507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative laryngeal electromyography parameters may correlate with improved outcomes following botulinum toxin injection for spasmodic dysphonia.
    Dwyer CD; Leclerc AA; Nandedkar SD; Young VN; Rosen CA
    Muscle Nerve; 2021 Apr; 63(4):525-530. PubMed ID: 33382480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum Toxin Dosing Trends in Spasmodic Dysphonia Over a 20-year Period.
    Namin AW; Christopher KM; Eisenbeis JF
    J Voice; 2017 Jan; 31(1):107-110. PubMed ID: 27005439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgery or botulinum toxin for adductor spasmodic dysphonia: a comparative study.
    Mendelsohn AH; Berke GS
    Ann Otol Rhinol Laryngol; 2012 Apr; 121(4):231-8. PubMed ID: 22606926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing long-term treatment response to botulinum toxin injection for spasmodic dysphonia.
    Kang MS; Lee SJ; Choi HS; Lim JY
    Clin Otolaryngol; 2021 Mar; 46(2):436-444. PubMed ID: 33260261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor.
    Orbelo DM; Duffy JR; Hughes Borst BJ; Ekbom D; Maragos NE
    J Voice; 2014 Jan; 28(1):123-7. PubMed ID: 24080335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onabotulinum toxin A dosage trends over time for adductor spasmodic dysphonia: A 15-year experience.
    Tang CG; Novakovic D; Mor N; Blitzer A
    Laryngoscope; 2016 Mar; 126(3):678-81. PubMed ID: 26308153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternating Unilateral Versus Bilateral Injections of Botulinum Toxin for the Treatment of Adductor Spasmodic Dysphonia.
    Lee SJ; Kang MS; Choi HS; Lim JY
    Otolaryngol Head Neck Surg; 2021 Apr; 164(4):815-820. PubMed ID: 32957836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum Toxin-A Dosing Trends for Adductor Spasmodic Dysphonia at a Single Institution Over 10 Years.
    Bradley JP; Barrow EM; Hapner ER; Klein AM; Johns MM
    J Voice; 2017 May; 31(3):363-365. PubMed ID: 27839987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of the OMNI vocal effort scale in the treatment of adductor spasmodic dysphonia.
    Shoffel-Havakuk H; Marks KL; Morton M; Johns MM; Hapner ER
    Laryngoscope; 2019 Feb; 129(2):448-453. PubMed ID: 30315575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.